氯苯唑酸对Ala97Ser遗传性转甲状腺素蛋白淀粉样心肌病[99mTc]Tc-焦磷酸盐显像的影响:初期显著降低且长期效应稳定
该回顾性分析前瞻性收集的队列研究纳入19例接受氯苯唑酸(61 mg/日)的Ala97Ser遗传性转甲状腺素蛋白淀粉样心肌病(ATTR-CM)患者和9例未接受疾病修饰药物的对照,评估[99mTc]Tc-PYP显像的系列变化。结果显示氯苯唑酸组治疗2年后容积性心/肺比值显著下降(3.86±0.91降至3.01±0.19,p<0.001),对照组无显著变化;治疗第一年内显著下降(3.75±0.37降至2.82±0.15,p=0.004),随后两年稳定。
要点
- 氯苯唑酸组治疗2年后容积性心/肺比值显著下降(3.86±0.91降至3.01±0.19,p<0.001),对照组无显著变化。
- 治疗第一年内容积性心/肺比值显著下降(3.75±0.37降至2.82±0.15,p=0.004)。
- 随后两年[99mTc]Tc-PYP摄取稳定,无进一步显著下降(2.82±0.15至2.83±0.18,p=0.934;3.20±0.14至3.09±0.16,p=0.404)。
核心结论
- 遗传性ATTR-CM患者接受氯苯唑酸治疗后[99mTc]Tc-PYP摄取显著降低,尤其在第一年内。
- 该效应似乎持续,但后续年份[99mTc]Tc-PYP摄取稳定,无进一步显著下降。
研究设计与样本
- 回顾性分析前瞻性收集的队列,纳入接受氯苯唑酸(61 mg/日)的Ala97Ser(A97S)遗传性ATTR-CM患者19例和未接受疾病修饰药物的A97S遗传性ATTR-CM对照9例。
- 氯苯唑酸组分为队列A(基线、1年、2年行[99mTc]Tc-PYP SPECT/CT扫描)和队列B(基线、2年、3年行扫描)。
- 测量视觉评分、平面心/对侧肺(H/CL)比值和容积性心/肺(H/L)比值。
主要发现
- 氯苯唑酸组随访2年后容积性H/L比值显著下降(3.86±0.91降至3.01±0.19,p<0.001),对照组无显著变化。
- 氯苯唑酸治疗第一年内容积性H/L比值显著下降(3.75±0.37降至2.82±0.15,p=0.004)。
- 随后两年[99mTc]Tc-PYP摄取稳定(2.82±0.15至2.83±0.18,p=0.934;3.20±0.14至3.09±0.16,p=0.404)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Tafamidis has shown potential in slowing disease progression in patients with transthyretin amyloid cardiomyopathy (ATTR-CM). This study aimed to evaluate serial changes on [99mTc]Tc-pyrophosphate (PYP) scintigraphy during tafamidis treatment for hereditary ATTR-CM. METHODS: We retrospectively analyzed a prospectively collected cohort of Ala97Ser (A97S) hereditary ATTR-CM patients treated with tafamidis (61 mg/day) and a control group comprising A97S hereditary ATTR-CM patients who had not received disease-modifying medications. The tafamidis group was further divided into two cohorts: cohort A received [99mTc]Tc-PYP SPECT/CT scans at baseline, 1 year, and 2 years; cohort B at baseline, 2 years, and 3 years. Visual score, planar heart to contralateral lung (H/CL) ratio, and volumetric heart to lung (H/L) ratio were measured. RESULTS: Nineteen patients were enrolled in the tafamidis group and nine in the control group. After 2 years of follow-up, a significant decrease in volumetric H/L ratio (3.86 ± 0.91 to 3.01 ± 0.19, p < 0.001) was noted in the tafamidis group, while there was no significant change in the control group. When evaluated over time, a significant decrease in volumetric H/L ratio was observed during the first year of tafamidis treatment (3.75 ± 0.37 to 2.82 ± 0.15, p = 0.004), followed by stable [99mTc]Tc-PYP uptake in the subsequent two years (2.82 ± 0.15 to 2.83 ± 0.18, p = 0.934 and 3.20 ± 0.14 to 3.09 ± 0.16, p = 0.404, respectively). CONCLUSION: A significant reduction in [99mTc]Tc-PYP uptake was observed in hereditary ATTR-CM patients after tafamidis treatment, particularly within the first year. While the effect appeared to be sustained, stable [99mTc]Tc-PYP uptake without further significant reductions was observed in the subsequent years.
引用
- Yu AL, Chen YC, Tsai CH, et al. Impact of Tafamidis on [99mTc]Tc-pyrophosphate Scintigraphy in Ala97Ser Hereditary Transthyretin amyloid cardiomyopathy: significant initial reduction with stable Long-Term effects. Eur J Nucl Med Mol Imaging. 2025. PMID: 39800807. doi:10.1007/s00259-025-07079-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。